The oldest hair-loss promise in the bathroom cabinet

Hair-loss panic has a particular sound. It is the small scrape of a brush being cleaned over the bin, the too-bright bathroom light, the silent arithmetic you do around a widening part line before breakfast. I know the temptation here. When a plant with more than 1,000 years of traditional use is suddenly described as a possible answer to androgenetic alopecia, it is hard not to lean forward.

Its botanical name is Polygonum multiflorum, also known in the literature as Pleuropterus multiflorus and in traditional Chinese medicine as He Shou Wu. A 2025 journal review argues that compounds from the root may influence several pathways involved in pattern hair loss: androgen signalling, follicle cycling, oxidative stress, inflammation and blood flow around the scalp. In press material around the review, first author Bixian Han put it more brightly.

Modern studies now confirm that this isn’t folklore; it’s pharmacology.
— Bixian Han, via EurekAlert

Han’s line will sell a lot of hope. It should also make us slow down. A better reading is not that an ancient root has suddenly become a proven hair-loss treatment. It is that an old remedy has collected enough mechanistic interest to deserve better human testing, while still carrying exactly the sort of safety baggage the beauty aisle tends to crop out.

The proof is doing less than the headline

Start with evidence shape. Researchers are gathering cell, animal and pharmacology work, then mapping those signals onto what we know about androgenetic alopecia. Useful, yes. Also early. Plausibility is a reasonable case for asking whether the herb, or one purified part of it, might do something clinically useful. But it is not the same as a robust trial in people who are watching their hair thin month by month.

Pattern hair loss is not a simple cosmetic sulk. A 2025 Nature Reviews Disease Primers article describes androgenetic alopecia as a progressive follicle-miniaturisation condition with hormonal, genetic and inflammatory layers; it also notes more than 380 genomic loci linked to the condition. In other words, this is not a single loose screw waiting for a botanical screwdriver.

Multi-pathway language can sound more persuasive than it is. Beauty marketing adores a compound that appears to do several things at once. Blocks DHT. Calms inflammation. Supports circulation. Protects follicles. By the time those verbs have stacked up, the reader feels as if a treatment has been demonstrated, when sometimes all that has been demonstrated is biological plausibility.

For formulation scientists, the insider question is still interesting: which constituents of Polygonum multiflorum actually matter, and does traditional processing change either the useful compounds or the risky ones? The review spends time on that terrain, which is where a serious product pipeline would have to begin. A capsule from the internet, a tonic from an unlabelled jar, and a standardised extract in a future clinical trial are not interchangeable objects. They just share a romantic name.

Here I become less enchanted by the thousand-year framing. Traditional use can be a clue. It can be a cultural record of repeated observation. It can also be a very long anecdote, complicated by shifting preparations, doses, patient selection and reporting. If a beauty brand tried to sell a new synthetic ingredient on that evidence alone, we would all be more suspicious.

The safety paragraph belongs near the front

Safety makes the ingredient comeback less cute and more revealing. Polygonum multiflorum has been linked to liver injury. Not in a vague wellness-blog way. In a clinical, documented, please-pay-attention way.

LiverTox, the NCBI Bookshelf database, puts it bluntly:

Polygonum multiflorum has been implicated in numerous reports of clinically apparent acute liver injury which can be severe and even fatal.
— LiverTox, NCBI Bookshelf

A line like that should sit beside every optimistic paragraph about follicle growth. LiverTox notes that injury has been reported with products containing the herb, including cases severe enough to require urgent transplant or to be fatal. Worst-case outcomes are uncommon in the overall landscape, but not trivial: up to 10% of clinically apparent cases in the LiverTox summary are described as fatal or requiring urgent transplant.

A dermatologist or toxicologist would not hear that and ask whether the root has a nice origin story. Dose would come first. Then preparation, contaminants, patient risk factors, monitoring, drug interactions and the kind of human evidence that could ever make the risk acceptable. Oral use would need special scrutiny, and researchers would have to ask if any future scalp treatment could isolate a useful effect without dragging the liver into the bargain.

Beauty culture still has a bad habit here. We talk about the scalp as if it floats separately from the rest of the body, a tiny garden that can be fed with oils, peptides, tonics and folklore. Bodies do not respect our categories. A substance taken by mouth is not a hair accessory. Even topicals can irritate, interact or create problems when the formulation is poor. Natural is a source descriptor, not a safety assessment.

For Australian readers, the practical translation is fairly unromantic: do not self-prescribe He Shou Wu supplements for hair loss, especially not if you have liver disease, take regular medication, are pregnant, or are trying to treat shedding that has not been diagnosed. Hair loss can come from iron deficiency, thyroid disease, stress, post-viral shifts, perimenopause, autoimmune conditions, traction, medication changes and plain old genetics. Your mirror cannot tell you which one it is.

The bathroom shelf is already impatient

Of course the market does not wait for perfect evidence. It rarely waits for adequate evidence. Over the past few years, hair-loss consumers have been trained to expect low-friction fixes: telehealth scripts, subscription serums, LED caps, dense supplement blends, TikTok scalp oils, before-and-after reels shot under lighting conditions that would make a cinematographer blush.

None of this means people are silly. Hair loss is intimate and slow and weirdly public. A BBC Culture analysis this week framed new hair-loss science through the experience of women waiting for better options, which is exactly the audience often flattened in older discussions of pattern loss. Men have long been sold baldness as fate, virility joke or transplant problem. Women are more often sold shame wrapped in a silk pillowcase.

At-home device companies understand that urgency. Wired’s recent red-light hair-growth guide is useful precisely because it treats these products as things people are already buying, not as fringe curiosities. Some devices may have evidence behind them. Others may simply feel active, expensive and therefore reassuring. Under bathroom lights, the difference is not always obvious when you are trying to decide whether the shedding has slowed.

Vox’s essay on drive-thru healthcare helps explain the wider mood. Hair loss has become one of those conditions increasingly handled through quick, transactional pathways: a form, a subscription, a discreet parcel. That can be convenient. It can also turn a symptom into a checkout flow before anyone has asked the more boring medical questions.

Here is why the Polygonum multiflorum story lands. It offers a pleasing contradiction: ancient but newly scientific, natural but pharmacological, familiar to tradition but fresh to the Western beauty cycle. Arriving in a category where people are exhausted by half-solutions gives it extra force. Minoxidil helps some users and irritates others. Finasteride carries its own debates and limitations, particularly for women. Procedures are expensive. Waiting feels like doing nothing.

A root remedy slips neatly into that frustration. Compared with a drug, it sounds softer. Compared with a random oil, it sounds more serious. Compared with a serum carrying a made-up complex name, it sounds culturally weighty. I can see the product copy already. I can also see the asterisk, smaller than it should be.

My fairest verdict is neither dismissal nor embrace. The review is a useful signal for researchers and formulation scientists. At best, it says there may be a real pharmacological story worth pulling apart: which molecule, at what dose, in which preparation, delivered how, tested against what comparator, measured over which months. Slow, unglamorous work. Less flattering on a product page.

Until that work exists, proof is still the missing ingredient. Not heritage. Not mechanism. Not a quote that turns folklore into pharmacology. Proof, in the annoying human sense: controlled trials, transparent safety data, standardised extracts, published adverse-event monitoring and results that do not rely on our willingness to mistake hope for hair.

I might be wrong about how this plays out. A future topical derived from Polygonum multiflorum could end up being genuinely useful, especially if researchers can separate any follicle benefit from the liver-risk history that shadows the herb. I would like that. Hair loss deserves more options, not fewer.

But if an ancient root is going to come back as a modern beauty treatment, it has to meet modern proof. The scalp is personal. The liver is not optional.